ASCO 2021: Summary Overview and Prospects 21 The efficacy and safety of zenocutuzumab in the treatment of advanced pancreatic cancer and NRG1 fusion solid tumors

NRG1 gene fusion is a rare but powerful cancer driver, which often occurs in pancreatic cancer , pancreatic cancer and other solid tumors.

HER3 belongs to the human epidermal growth factor receptor (HER) family.

The selected patients (pts) have advanced NRG1+ pancreatic cancer, non-small cell lung cancer ( NSCLC ) and other solid tumors, have received standard treatment before, are ≥18 years old, ECOG performance status ≤1, have sufficient organ function, and are predictable Disease (RECIST v1.

Fifty-one cancer patients with NRG1+ have been treated with zenocutuzumab, 37 of whom have participated in the eNRGy study and 14 have participated in the EAP study.

Among these 51 patients, 10 patients with pancreatic cancer, 18 patients with NSCLC and 5 patients with other solid tumors all had predictable diseases.

The investigator evaluated the ORR of pancreatic cancer patients as 40% (4/10), 7/10 patients had tumor regression, and the disease control rate was 90%.

In patients with metastatic KRAS wild-type NRG1+ pancreatic cancer, zenocutuzumab induced tumor regression and biomarker response, with minimal toxicity.

https://meetinglibrary.